RxDoctor Payments Data

Julie Cortes, PA

Physician Assistant · Bakersfield, CANPI 1710450226

Payments from drug & device makers

$8,909in general payments, 2019–2025

Across 379 payments — averaging $23.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Lilly USA, LLC$849
  • Novo Nordisk$826
  • Xeris Pharmaceuticals, Inc.$753
  • Abbott$448
  • Boehringer Ingelheim$320
  • plus $3K from 39 others

What the payments were for

  • Travel & lodging$1,15513%
  • Food & beverage$7,64386%
  • Education$1121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,909 in reported general payments places this provider in the 95th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$4,828
Medicare patients
30
Services billed
138

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide230$241,340
MounjaroTirzepatide104$110,608
JardianceEmpagliflozin135$99,428
FarxigaDapagliflozin Propanediol109$81,762
TrulicityDulaglutide69$75,435
Evenity (2 Syringes)Romosozumab-Aqqg18$42,991
Synjardy XrEmpagliflozin/Metformin Hcl39$33,026
Tresiba Flextouch U-200Insulin Degludec30$21,704
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog27$16,855
Xigduo XrDapaglifloz Propaned/Metformin15$16,635
RybelsusSemaglutide13$14,479
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog39$12,952
Tresiba Flextouch U-100Insulin Degludec33$12,190
Humalog Kwikpen U-200Insulin Lispro11$8,953
TradjentaLinagliptin14$8,805

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$826$255,819243 claims
Lilly USA, LLCMounjaro, Trulicity$849$186,043173 claims
Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta$320$141,259188 claims
AstraZenecaFarxiga$294$81,762109 claims
AmgenEvenity (2 Syringes)$294$42,99118 claims
AbbVieSynthroid$64$1,17916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →